US infections from antibiotic-resistant NDM-CRE bacteria rose 69% from 2019 to 2023 NDM-CRE cases increased 460%, from 0.25 to 1.35 per 100,000 people between 2019 and 2023 Only two costly, IV-administered antibiotics effectively treat NDM-CRE infections
